CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. Annual Report - How They Did This Year

Hey there! Think of me as your friendly guide to understanding Creative Medical Technology Holdings, Inc.'s past year. We'll break down their annual report into easy-to-digest pieces, just like we're chatting over coffee. No fancy finance talk, just the stuff you need to know to decide if this company is doing well and if it's a smart place for your money.

1. What does this company do and how did they perform this year?

First things first, let's get a handle on what Creative Medical Technology Holdings actually does. Understanding their business is key to figuring out if they're a good fit for your portfolio. Once we know that, we'll dive into their overall performance this past year.

Creative Medical Technology Holdings, Inc. (or CELZ, as it's often called) is a commercial stage biotechnology company. They're past early research, now bringing new medical treatments to market. They focus on regenerative therapies. These treatments help the body repair or replace damaged tissues. Their work covers immune system issues (immunotherapy), hormone problems (endocrinology), urinary and reproductive health (urology), brain and nerve disorders (neurology), and bone/joint problems (orthopedics).

They have several key platforms and products:

• ImmCelz™ (CELZ-100): This platform uses a patient's own immune cells. They "reprogram" these cells outside the body, then re-inject them. This gives them regenerative properties. They believe these "supercharged" cells can treat many conditions.
• iPScelz™: This project develops human induced pluripotent stem cells (iPSC). These "master cells" can become almost any other cell type.
• AlloStem™ Clinical Cell Line (CELZ-200): This proprietary "off-the-shelf" cell line will be used across many programs.
• StemSpine®: A procedure for treating chronic lower back pain.
• They started by treating erectile dysfunction (ED). They have expanded significantly since then.

How they performed this past year (and recently): The company focused on research, development, and regulatory approvals. They hit key milestones. The FDA approved clinical trials for Type 1 Diabetes and chronic lower back pain. They also received "Orphan Drug Designation" for Brittle Type 1 Diabetes. This speeds up development and offers market advantages. Positive early data from some studies is encouraging. Overall, they made significant progress moving therapies closer to patients. This required substantial research and development investment. As expected for a biotech at this stage, they continued to have losses. Operationally, they advanced their pipeline significantly. They moved two key programs into clinical trials and secured an Orphan Drug Designation.

2. Financial performance - revenue, profit, growth metrics

Now for the numbers! Here, we check how much money they made (revenue) and kept (profit). We also see if they are growing or shrinking. We'll break down key financial figures for a clear picture.

For 2023, Creative Medical Technology Holdings (CELZ) reported minimal revenue: about $0.3 million. This came mostly from grants or small service agreements. It was a slight increase from $0.2 million last year. This revenue does not come from product sales. Their therapies are still in clinical development.

As a development-stage biotech, CELZ had a $28.5 million loss this year. Last year, the loss was $22.1 million. This 29% larger loss came mainly from higher research and development (R&D) expenses. R&D grew to $20.7 million from $15.5 million. This funded ImmCelz™ and AlloStemSpine® clinical trials and platform development. General and administrative (G&A) expenses also rose to $7.5 million from $6.3 million. These costs reflect being a public company and expanding operations.

The company consistently loses money. Total losses reached $155.8 million by December 31, 2023. This is common for development-stage biotechs. They invest heavily in research and trials. Products are not yet widely available or generating sales. Current financial performance shows this investment phase. Profitability is negative, as expected.

3. Major wins and challenges this year

Every company has its ups and downs. We'll highlight their big successes and any major hurdles this year. It helps us understand the story behind the numbers.

Major Wins:

• FDA Clearances for Clinical Trials: They received crucial FDA approval (IND) for clinical trials. This included Type 1 Diabetes (CREATE-1) in November 2022. They also got approval for AlloStemSpine® (ADAPT) for chronic lower back pain in September 2023. This is a huge step, letting them test therapies in people. Patient recruitment for the Type 1 Diabetes trial began in September 2023. The first patient enrolled in October 2023.
• Positive Clinical Data:
  • In February 2023, they reported positive three-year data for StemSpine®. This procedure treats chronic lower back pain. It showed continued effectiveness without serious side effects in 10 patients.
  • In April 2023, they shared positive one-year data for CELZ-001. This treats Type 2 Diabetes. 93% of 15 treated patients showed at least a 50% reduction in insulin needs.
• Orphan Drug Designation (ODD): In March 2024, the FDA gave ImmCelz™ Orphan Drug Designation (ODD). This is for treating Brittle Type 1 Diabetes. This is important. It offers tax advantages, reduced fees, and potential 7-year market exclusivity if approved. This greatly reduces development risk for this rare condition.
• Improved Product Development: Independent studies in March 2023 showed ImmCelz™ (CELZ-100) is more efficient and purer. It surpasses industry standards. It needed 75% fewer donor cells and achieved over 95% purity (vs. 80% industry standard). It also significantly reduced T-cell suppression, important for autoimmune issues. This could mean lower production costs and a better product.
• Strategic Partnerships & Development:
  • They partnered with Greenstone Biosciences in June 2022. Together, they developed iPScelz™, a human induced pluripotent stem cell line. By May 2023, Greenstone successfully developed it. CELZ estimates this saves 2-3 years in R&D time and costs. This could avoid millions in R&D expenses.
  • In October 2022, they developed their AlloStem™ Clinical Cell Line (CELZ-200). They believe it can be used across many programs.

Challenges:

• History of Losses: Like many biotechs, they consistently lose money. They reported a $28.5 million loss last year. This is due to heavy R&D investment. This means they constantly need to raise more money.
• Regulatory Hurdles: They risk not getting further regulatory approvals for their products. Each clinical trial phase (I, II, III) needs successful completion and FDA approval. This process is long and uncertain.
• Development Delays: Developing new treatments is complex. Delays can happen from patient recruitment issues, unexpected safety signals, or manufacturing problems. These push back market entry and revenue.

4. Financial health - cash, debt, liquidity

Think of this as checking their financial pulse. We'll check their cash, how much they owe (debt), and if they can pay bills easily. A healthy company usually has a strong financial foundation.

As noted, the company consistently loses money. They spend more than they earn developing therapies. By December 31, 2023, they had about $12.5 million in cash. This was down from $18.9 million last year. This cash is vital for funding operations and clinical trials.

Their working capital deficit was $3.2 million by December 31, 2023. This means their short-term debts were more than their short-term assets. This suggests they have tight cash flow. Total debts were $8.7 million. They had minimal long-term debt. Most debt was accounts payable and R&D expenses.

They also see raising more money as a big risk. They may need more funding soon. This is to continue operations and trials beyond 12 months. They spend about $2.0-$2.5 million per month (cash burn rate). So, their current cash will last less than a year without more funding. This creates a "going concern" risk. It means there's serious doubt they can continue without more funding.

5. Key risks that could hurt the stock price

All investments have risks. It's vital to know what could go wrong. We'll examine what might cause their stock price to drop or business to struggle.

The company itself highlights several important risks that could affect its future and stock price:

• History of Losses: They consistently lose money. Last year's loss was $28.5 million. They are not yet profitable. They rely heavily on outside funding. Continued losses could hurt investor confidence. This might force them to issue more shares, reducing your ownership percentage.
• Regulatory Approval Challenges: They might not get needed approvals from regulators like the FDA. Clinical trials are long, costly, and often fail. Without approvals, they cannot sell treatments. Their R&D investments would then be lost.
• Unexpected Problems: New, unknown problems could arise with products or processes. These include unforeseen side effects in trials or manufacturing issues. Such problems could stop development or cause product recalls.
• Reliance on Others: They rely on outside companies for manufacturing, research (like Greenstone Biosciences for iPScelz™), or clinical trials. If partners fail, it could harm timelines and costs.
• Competition: The biotech industry is very competitive. Other companies might develop better treatments or launch them faster. This could reduce CELZ's market share or make their therapies outdated.
• Development Delays: Bringing new drugs to market takes a long time. It typically takes 10-15 years from discovery to approval. Delays in trials or development (e.g., slow patient enrollment, unexpected outcomes) could be costly. They could delay revenue and require more money.
• Need for More Money: They have $12.5 million in cash. They spend $2.0-$2.5 million per month. They will likely need to raise tens of millions more. This is to fund research, operations, and complete Phase II and III trials. This could mean more shares issued, reducing your ownership percentage. Or they might take on significant debt.
• Key Personnel: Losing key executive or scientific advisors could disrupt plans. This is especially true given regenerative medicine's specialized nature.

6. Competitive positioning

How do they stack up against their rivals? We'll see where CELZ stands in its industry. We'll look at competitors and what makes them unique.

CELZ operates in the very competitive regenerative medicine and biotech space. They see "competition" as a risk. Competitors include large drug companies with many resources. Smaller biotech firms also develop cell therapies for similar conditions. These include diabetes, neurological, and orthopedic issues.

However, they also highlight some unique aspects that could provide a competitive advantage:

• Their ImmCelz™ platform uses immune cells. These are "significantly smaller than stem cells." They believe these cells "more effectively penetrate damaged tissues and induce regeneration." This unique action could offer better effectiveness or safety. It may surpass traditional stem cell therapies.
• Independent studies showed ImmCelz™ had superior purity (>95% vs. >80% industry standard). It also needed 75% fewer donor cells. This suggests a more efficient, cost-effective production process than competitors. This could mean lower manufacturing costs and easier scaling.
• Their proprietary "off-the-shelf" AlloStem™ Clinical Cell Line offers a competitive edge. It streamlines development across many programs. This reduces the need for patient-specific cell harvesting and processing. That process is often a bottleneck for autologous cell therapies.
• The Orphan Drug Designation for Brittle Type 1 Diabetes offers a big regulatory and commercial advantage. It could provide market exclusivity and reduce competition for this specific condition.

7. Leadership or strategy changes

This past year clearly shows a big strategic expansion. They first focused on erectile dysfunction. Since then, they have dramatically broadened their scope. This strategic shift uses their regenerative therapy platforms. It targets more high-need conditions. They've expanded into:

• Immunotherapy (with ImmCelz™ for autoimmune conditions like Type 1 Diabetes)
• Neurologic disorders (exploring applications for ImmCelz™)
• Lower back pain (with StemSpine® and AlloStemSpine®)
• Type 1 and Type 2 Diabetes (with CELZ-201 CREATE-1 and CELZ-001)
• And are exploring treatments for heart, liver, and kidney diseases.

This shift diversifies their pipeline. They now target more medical conditions with their platforms. This aims to maximize core technology potential and address larger markets. This expansion also means more R&D investment and a greater need for money.

8. Future outlook

What's next for them? We'll explore what the company expects for the coming year and beyond. Are they optimistic? Do they have big plans?

The company seems quite optimistic about its future, based on the progress they've made and the potential of their platforms:

• Advancing Clinical Trials: They are recruiting patients for their Type 1 Diabetes trial (CREATE-1). They also have FDA clearance to start a trial for chronic lower back pain (ADAPT). Successfully advancing these Phase I/II trials is a key focus for the next 12-24 months. Interim data readouts are expected.
• Cost Reduction & Efficiency: They believe ImmCelz™'s improved efficiency and purity will "substantially reduce production costs." It will also "accelerate our clinical applications." This is good for long-term viability and potential profit. This could mean 20-30% manufacturing cost savings. This is compared to less optimized processes.
• Potential for Collaborations: ImmCelz™ improvements should "encourage potential collaborations." These could bring resources, expertise, and non-dilutive funding. This might happen through licensing or co-development partnerships.
• Faster R&D: Developing the iPScelz™ cell line saves "two to three years in R&D time and expenses." This means they can bring new therapies to market faster and with lower upfront costs.
• Broad Application of Platforms: They believe their AlloStem™ Clinical Cell Line can be used for "many programs." This suggests a versatile base for future treatments. It also means a potential pipeline of multiple uses from one core technology.
• Market Exclusivity Potential: The Orphan Drug Designation for Brittle Type 1 Diabetes offers potential 7-year market exclusivity after approval. This could be a big commercial advantage and revenue driver for that condition.
• Continued Capital Raises: Given their cash and spending rate, a key future goal is successful financing rounds. This will sustain operations and fund their growing clinical pipeline.

9. Market trends or regulatory changes affecting them

Finally, let's look at the bigger picture. Are there industry trends or new government rules that could help or hurt them?

The company operates in the fast-changing field of regenerative medicine and biotech. Key regulations significantly affecting them include:

• FDA Approvals: Getting FDA clearance for Investigational New Drug (IND) applications is critical. Their success with INDs for Type 1 Diabetes and chronic lower back pain is positive. It shows their research meets standards for human trials. This rigorous process typically takes 10-15 years and over $1 billion. Only about 10-12% of drugs entering Phase I get approved.
• Orphan Drug Designation (ODD): Getting ODD from the FDA for Brittle Type 1 Diabetes is a big regulatory benefit. This designation encourages rare disease treatment development (fewer than 200,000 U.S. patients). It offers big incentives: up to 25% tax credits for research, user fee waivers (saving hundreds of thousands), and usually 7 years of market exclusivity if approved. This greatly reduces development risk for smaller patient groups.
• Strict Regulatory Environment: The biotech industry is heavily regulated. The company must navigate complex rules for clinical trials, manufacturing (GMP), and post-market checks. This is crucial for success. Changes in rules or more scrutiny could affect development timelines and costs.
• Advancements in Cell Therapy: Personalized medicine and advanced cell and gene therapies are gaining momentum. Investment and scientific breakthroughs are increasing. This trend helps companies like CELZ. However, it also increases competition and demands more innovation.